comparemela.com

Latest Breaking News On - Prnewswire fusion pharmaceuticals inc - Page 7 : comparemela.com

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayNiowave incInvestor relations corporate communicationsFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incCompany board of directorsNasdaq listing ruleResponse inhibitorsSenior directorInvestor relationsCorporate communicationsHealth care amp hospitalsMedical pharmaceuticalsNew products amp services

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, April 5, 2023 /PRNewswire/ Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as. | June 20, 2023

United statesAmanda crayCompany board of directorsPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsNiowave incNasdaq listing ruleResponse inhibitorsSenior directorInvestor relationsCorporate communications

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayFusion pharmaceuticals incWoodline master fundNiowave incDeerfield management companyAmerican association for cancer researchPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsExecutive officer john valliantAvidity partnersFederated hermes kaufmann fundsPerceptive advisorsAmerican association

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayFusion pharmaceuticals incNiowave incCompany board of directorsFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsNasdaq listing ruleResponse inhibitorsSenior directorInvestor relationsCorporate communicationsFusion pharmaceuticals inc

Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayFusion pharmaceuticals incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsAnnual cowen healthcare conferenceChief executive officer john valliantResponse inhibitorsInvestor relationsFusion pharmaceuticals inc

vimarsana © 2020. All Rights Reserved.